{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-001987","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.943411+00:00","generated_at":"2026-06-05T08:57:52.854212+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Voyager Therapeutics reports Q4 net income $56.4M, pro-forma cash $431M, pipeline milestones","bullets":["Q4 collaboration revenue $90.1M (vs -$1.6M YoY), net income $56.4M (vs loss $23.6M).","FY 2023 collaboration revenue $250.0M (vs $40.9M), net income $132.3M (vs loss $46.4M).","Pro-forma cash $431M after Novartis $100M and Jan 2024 $100M public offering; runway into 2027.","Selected development candidates: SOD1 ALS gene therapy (IND mid-2025) and Friedreich's ataxia (triggered $5M milestone, clinic 2025).","Novartis collaboration: $80M upfront + $20M equity, up to $1.2B milestones; VY-TAU01 IND expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-001987","json":"https://secwatch.observer/filing/0001558370-24-001987.json","markdown":"https://secwatch.observer/filing/0001558370-24-001987.md","text":"https://secwatch.observer/filing/0001558370-24-001987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024001987/0001558370-24-001987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024001987/vygr-20240228x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:57:52.854212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5bfffd93bfb27c63dfe1b7ed388663fa98a6a66","claim":"Voyager Therapeutics, Inc. reported Q4 2023 results: revenue $90.1 million, net income $56.4 million.","evidence_excerpt":"Voyager had collaboration revenue of $90.1 million for the fourth quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024001987/0001558370-24-001987-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2023"},{"label":"Revenue","value":"$90.1 million"},{"label":"Net income","value":"$56.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}